Strategic partnerships Norbrook has recently pursued and announced strategic sales alliances with Provita Animal Health to bolster support for livestock farmers across Great Britain and Northern Ireland, presenting an opportunity to co-sell or co-market veterinary products and expand distributor networks.

Distributor expansion Solvet has been named the trusted sole distributor for Norbrook in Canada, signaling a channel-focused expansion that can be leveraged to explore additional regional distribution deals, localized regulatory support, and market-specific product adaptations.

Product divestment/showcase Norbrook exited its feline hyperthyroidism drug Thyronorm (Fel a norm in the US) to Virbac in December 2025, indicating a strategic portfolio reshuffle; sales teams can identify adjacent or replacement product opportunities and cross-sell within the residual portfolio.

Multi-year investment A multi-year capital investment program to upgrade manufacturing, labs, and IT infrastructure signals capacity readiness and potential for scaled contract manufacturing, private label opportunities, or partner-driven product development in faster-growing segments.

Global veterinary focus As a leading global veterinary pharma provider with a wide product scope for farm and companion animals, there is upside in pursuing cross-border tenders, increased export opportunities, and strategic partnerships with large veterinary distributors in regions underpenetrated by Norbrook.